Drug Pipeline

PI3K-beta Inhibitor GSK2636771 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
0
Recruiting
2
Top Sponsors
Active Studies by Phase
Phase 2
3
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT04439149 Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes… Advanced Lymphoma Active, Not Recruiting
NCT04439188 Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of… Advanced Lymphoma Active, Not Recruiting
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced… Advanced Lymphoma Active, Not Recruiting
Phase 1/2
NCT03131908 Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab… Melanoma and Other Malignant Neoplasms of Skin Active, Not Recruiting
Sponsors Running PI3K-beta Inhibitor GSK2636771 Trials
National Cancer Institute (NCI) (3) M.D. Anderson Cancer Center (1)
Disease Areas
Multiple Myeloma (3) Melanoma (2) Lung Cancer (1) Breast Cancer (1) Prostate Cancer (1) Pancreatic Cancer (1) Gastric Cancer (1) Ovarian Cancer (1) Cervical Cancer (1) Endometrial Cancer (1)
Get alerts when PI3K-beta Inhibitor GSK2636771 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free